The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Estrogen and Progestin Compared with Simvastatin for Hypercholesterolemia in Postmenopausal Women
Open accessAbstract
BACKGROUND: Postmenopausal estrogen therapy has favorable effects on serum lipoproteins in women with normal serum lipid levels, but the effect of combined estrogen and progestin therapy on lipoproteins in women with hypercholesterolemia has not been determined, nor has it been directly compared with the effect of conventional lipid-lowering therapy. METHODS: In a randomized crossover trial, we studied 58 postmenopausal women with fasting serum total cholesterol levels greater than 250 mg per deciliter. Each woman received simvastatin (10 mg daily) for eight weeks and postmenopausal hormone therapy (up to 1.25 mg of conjugated equine estrogens daily, along with 5 mg of medroxyprogesterone acetate daily) for eight weeks, with an eight-week washout period between the two treatment phases. RESULTS: At base line, the mean (+/-SD) cholesterol values were as follows: total cholesterol, 305+/-39 mg per deciliter; high-density lipoprotein (HDL) cholesterol, 62+/-19 mg per deciliter; and low-density lipoprotein (LDL) cholesterol, 217+/-39 mg per deciliter. For total cholesterol, the mean decrease with hormone therapy was 14 percent (95 percent confidence interval, 11 to 16 percent) and the mean decrease with simvastatin was 26 percent (95 percent confidence interval, 23 to 29 percent). For LDL cholesterol, the mean decrease was 24 percent (95 percent confidence interval, 20 to 28 percent) with hormone therapy and 36 percent (95 percent confidence interval, 32 to 40 percent) with simvastatin. The effect of simvastatin was significantly greater than that of hormone therapy (P<0.001). HDL cholesterol increased similarly with hormone therapy (mean increase, 7 percent; 95 percent confidence interval, 2 to 12 percent) and simvastatin (mean increase, 7 percent; 95 percent confidence interval, 4 to 10 percent). Triglyceride levels increased with hormone therapy (mean increase, 29 percent; 95 percent confidence interval, 15 to 42 percent) but decreased with simvastatin (mean decrease, 14 percent; 95 percent confidence interval, 8 to 20 percent). Lp(a) lipoprotein decreased with hormone therapy (mean decrease, 27 percent; 95 percent confidence interval, 20 to 34 percent), but not with simvastatin. CONCLUSIONS: In postmenopausal women with hypercholesterolemia, therapy with estrogen plus progestin has beneficial effects on lipoprotein levels. Hormone therapy may be an effective alternative to treatment with simvastatin, especially in women with normal triglyceride levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Walsh, B. W., Schiff, I., Rosner, B., Greenberg, L., Ravnikar, V., & Sacks, F. M. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110243251702 · Cited by 1,152
Menopause and Risk Factors for Coronary Heart Disease
Matthews, K. A., Meilahn, E., Kuller, L. H., Kelsey, S. F., Caggiula, A. W., & Wing, R. R. (1989) · New England Journal of Medicine · doi:10.1056/nejm198909073211004 · Cited by 1,040
Plasma triglyceride and coronary heart disease
Austin, M. A. (1991) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.11.1.2 · Cited by 697
JACOBS, D. R., MEBANE, I. L., BANGDIWALA, S. I., CRIQUI, M. H., TYROLER, H. A., & PROGRAM, F. T. L. R. C. (1990) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115483 · Cited by 452
Plasma Lipoprotein Levels as Predictors of Cardiovascular Death in Women
Bass, K. M. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410190045006 · Cited by 331
Cited by
Updated definitions of healthy ranges for serum alanine aminotransferase levels
Prati, D., Taioli, E., Zanella, A., Torre, E. D., Butelli, S., Del Vecchio, E., Vianello, L., Zanuso, F., Mozzi, F., Milani, S., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00006 · Cited by 1,445
Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity
Jones, M. E. E., Thorburn, A. W., Britt, K. L., Hewitt, K. N., Wreford, N. G., Proietto, J., Oz, O. K., Leury, B. J., Robertson, K. M., Yao, S., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.23.12735 · Cited by 729
Estrogen replacement therapy, atherosclerosis, and vascular function
Mikkola, T. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00466-7 · Cited by 420
Shlipak, M. G. (2000) · JAMA · doi:10.1001/jama.283.14.1845 · Cited by 371
Teede, H. J., Dalais, F. S., Kotsopoulos, D., Liang, Y.-L., Davis, S., & McGrath, B. P. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7645 · Cited by 292
Self-citation
Metadata
- Authors
- Darling, G. M., Johns, J. A., McCloud, P. I., & Davis, S. R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1997-08-28
- Volume
- 337
- Issue
- 9
- Pages
- 595-601
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2046981726
- Cited by
- 189
- References
- 6
- FWCI
- 16.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Estrogen and Progestin Compared with Simvastatin for Hypercholesterolemia in Postmenopausal Women. https://app.cochat.ai/papers/10.1056/nejm199708283370903
- The paper
- Darling, G. M., Johns, J. A., McCloud, P. I., & Davis, S. R. (1997). Estrogen and Progestin Compared with Simvastatin for Hypercholesterolemia in Postmenopausal Women. New England Journal of Medicine. https://doi.org/10.1056/nejm199708283370903
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.